Investments
262Portfolio Exits
59Partners & Customers
2Service Providers
3About Novo Holdings
Novo Holdings is the holding company of the Novo Group and manages the investment assets of the Novo Nordisk Foundation. It invests in life science companies at all stages of development and in a broad portfolio of equity and fixed-income securities. Novo Holdings was formerly known as Novo. The company was founded in 1999 and is based in Hellerup, Denmark.
Want to inform investors similar to Novo Holdings about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Novo Holdings News
Sep 29, 2023
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing. The Series C financing was co-led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, which were joined by new investors, Vida Ventures, Wellington Management, Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel Company), Catalio Capital Management, and Piper Heartland. Current investors, including Novo Holdings A/S, Norwest Venture Partners, F-Prime Capital, Pivotal bioVenture Partners, and RiverVest Venture Partners, also participated. In conjunction with the financing, Gianna Hoffman-Luca, Ph.D., of Perceptive Xontogeny Venture Funds, and Jill Carroll of SR One, joined Avalyn's Board of Directors. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Novo Holdings Investments
262 Investments
Novo Holdings has made 262 investments. Their latest investment was in Avalyn as part of their Series C on September 9, 2023.
Novo Holdings Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/27/2023 | Series C | Avalyn | $175M | No | Catalio Capital Management, Eventide Asset Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Perceptive Advisors, Piper Heartland Healthcare Capital, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, SR One, Surveyor Capital, Vida Ventures, and Wellington Management | 2 |
9/19/2023 | Unattributed VC | HPNow | $14.94M | Yes | AP Ventures, Denmark’s Export and Investment Fund, Evonik Venture Capital, MatiTech, Novo Holdings, and Undisclosed Investors | 2 |
8/8/2023 | Series A | Bactolife | $33M | Yes | 2 | |
8/7/2023 | PIPE - II | |||||
7/28/2023 | Series D |
Date | 9/27/2023 | 9/19/2023 | 8/8/2023 | 8/7/2023 | 7/28/2023 |
|---|---|---|---|---|---|
Round | Series C | Unattributed VC | Series A | PIPE - II | Series D |
Company | Avalyn | HPNow | Bactolife | ||
Amount | $175M | $14.94M | $33M | ||
New? | No | Yes | Yes | ||
Co-Investors | Catalio Capital Management, Eventide Asset Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Perceptive Advisors, Piper Heartland Healthcare Capital, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, SR One, Surveyor Capital, Vida Ventures, and Wellington Management | AP Ventures, Denmark’s Export and Investment Fund, Evonik Venture Capital, MatiTech, Novo Holdings, and Undisclosed Investors | |||
Sources | 2 | 2 | 2 |
Novo Holdings Portfolio Exits
59 Portfolio Exits
Novo Holdings has 59 portfolio exits. Their latest portfolio exit was Altasciences Clinical Research on September 21, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/21/2023 | Divestiture | 2 | |||
2/9/2023 | Reverse Merger | 4 | |||
12/29/2022 | Reverse Merger | 5 | |||
Date | 9/21/2023 | 2/9/2023 | 12/29/2022 | ||
|---|---|---|---|---|---|
Exit | Divestiture | Reverse Merger | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 4 | 5 |
Novo Holdings Acquisitions
13 Acquisitions
Novo Holdings acquired 13 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/20/2023 | Debt | $129.3M | Take Private | 10 | ||
6/21/2023 | Acquired | 10 | ||||
9/23/2022 | Other | Acquired | 1 | |||
1/4/2022 | ||||||
1/3/2022 |
Date | 9/20/2023 | 6/21/2023 | 9/23/2022 | 1/4/2022 | 1/3/2022 |
|---|---|---|---|---|---|
Investment Stage | Debt | Other | |||
Companies | |||||
Valuation | |||||
Total Funding | $129.3M | ||||
Note | Take Private | Acquired | Acquired | ||
Sources | 10 | 10 | 1 |
Novo Holdings Partners & Customers
2 Partners and customers
Novo Holdings has 2 strategic partners and customers. Novo Holdings recently partnered with Industriens Pension, Urban Partners, and DSB Ejendomme on February 2, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/7/2023 | Partner | Denmark | Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen . | 2 | |
11/19/2019 | Partner |
Date | 2/7/2023 | 11/19/2019 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | Denmark | |
News Snippet | Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen . | |
Sources | 2 |
Novo Holdings Service Providers
5 Service Providers
Novo Holdings has 5 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acquired - II | Counsel | General Counsel | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acquired - II | ||
Provider Type | Counsel | ||
Service Type | General Counsel |
Partnership data by VentureSource
Novo Holdings Team
16 Team Members
Novo Holdings has 16 team members, including current Chief Executive Officer, Kasim Kutay.
Name | Work History | Title | Status |
|---|---|---|---|
Kasim Kutay | Chief Executive Officer | Current | |
Name | Kasim Kutay | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
Compare Novo Holdings to Competitors
Alexandra Instituttet is an information technology consultant and developer. It provides artificial intelligence, digital green transition, cyber security, digital health, and more. It was founded in 1999 and is based in Aarhus, Denmark.
GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.
Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.
7 Hills Pharma develops an immunotherapy platform to boost the efficiency of immune checkpoint inhibitors and vaccines against infectious diseases. It boosts the anticancer activity of multiple novel cell-based immunotherapies, giving consumers access to medicines that boost the potency of novel immuno-oncology medications and vaccinations for infectious diseases. The company was founded in 2015 and is based in Houston, Texas.
Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice. Healios was founded in 2012 and is based in Basel, Switzerland.
Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
